Illumina, Investor Drop Fight Over Poison Pill In Roche Bid

Law360, New York (July 31, 2012, 5:04 PM EDT) -- Gene sequencing company Illumina Inc. and one of its shareholders agreed Monday to resolve the investor's suit, which he had intended to use as an antidote to Illumina's poison pill efforts to block Roche Holding AG's hostile takeover attempt.

The joint motion for dismissal, filed in California federal court, squelches one of the last still-smoldering pieces of Roche’s failed $6.2 billion buyout bid for Illumina, rejected by Illumina’s board even after the Swiss company sweetened a $5.7 billion offer it had leveled early this year....
To view the full article, register now.